tiprankstipranks
Cibus (CBUS)
NASDAQ:CBUS
US Market

Cibus (CBUS) Earnings Dates, Call Summary & Reports

Compare
534 Followers

Earnings Data

Report Date
May 08, 2025
TBA Not Confirmed
Period Ending
2025 (Q1)
Consensus EPS Forecast
-0.51
Last Year’s EPS
-1.12
Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Mar 20, 2025
|
% Change Since: -4.57%
|
Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in strategic partnerships, regulatory advancements, and market expansion, particularly in gene editing and sustainable ingredients. However, the company faces challenges with limited cash reserves and the need for additional financing. The transition in leadership is noteworthy, but the overall narrative remains one of cautious optimism about future revenue opportunities.
Company Guidance
During the Cibus Fourth Quarter 2024 Results Conference Call, the company provided comprehensive guidance on its strategic initiatives and financial outlook. Cibus highlighted its progress in developing gene-edited productivity traits, particularly focusing on rice and canola crops, with significant advancements in herbicide tolerance traits and disease resistance. The company emphasized its proprietary Rapid Trait Development System (RTDS) that allows for precise gene editing similar to conventional breeding methods. Cibus reported a cash balance of $14.4 million as of December 31, 2024, and expects its existing cash and cash equivalents to fund operations into late Q3 2025, following a $21.6 million net proceeds from a direct offering. For the fourth quarter, research and development expenses were reported at $12.4 million, while selling, general, and administrative expenses were $6.8 million. The net loss was $25.8 million, an improvement from the previous year's $277.2 million, mainly due to cost reduction efforts. Moving forward, Cibus plans to focus on commercializing its gene-edited traits, leveraging favorable regulatory changes in the EU and expanding its global market potential.
Strategic Partnerships and Collaborations
Cibus formed significant collaborations with RTDC Corporation Limited and Albaugh LLC for herbicide-resistant rice traits, and with Biographica for AI-based gene discovery. These partnerships aim to enhance commercialization efforts and disease resistance in crops.
Advances in Regulatory Environment
The EU Council's negotiation mandate on new genomic techniques regulation is expected to harmonize the global regulatory landscape for gene editing, opening new markets for Cibus' products.
Expansion in Key Markets
Cibus has agreements with major rice seed companies in North and Latin America, covering around 40% of estimated accessible rice acres in these regions. Additionally, Cibus is making progress with its Sclerotinia resistance and HT2 traits in canola and winter oilseed rape.
Financial Management and Cost Reduction
Cibus reported a decrease in R&D expenses by $1.8 million year-over-year, primarily due to cost-saving initiatives and reduced personnel costs. This led to an improvement in net loss, excluding goodwill impairment, by approximately $2 million.
Progress in Sustainable Ingredients Program
Cibus is advancing its sustainable ingredients program with a large multinational CPG partner and expects nominal revenues from biofragrance products later in the year.
---

Cibus (CBUS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

CBUS Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
May 08, 20252025 (Q1)
-0.51 / -
-1.12
Mar 20, 20252024 (Q4)
-0.68 / -0.87
-12.5993.09% (+11.72)
Nov 07, 20242024 (Q3)
-0.87 / -7.63
-1.59-379.87% (-6.04)
Aug 08, 20242024 (Q2)
-0.81 / -1.14
-3.0562.62% (+1.91)
May 09, 20242024 (Q1)
-1.01 / -1.12
-5.4579.45% (+4.33)
Mar 21, 20242023 (Q4)
-1.43 / -12.59
-3-319.67% (-9.59)
Nov 09, 20232023 (Q3)
-1.17 / -1.59
-6.575.54% (+4.91)
Aug 09, 20232023 (Q2)
-0.30 / -3.05
-2.5-22.00% (-0.55)
May 01, 20232023 (Q1)
-3.00 / -5.45
-722.14% (+1.55)
Mar 02, 20232022 (Q4)
-5.50 / -3.00
-966.67% (+6.00)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

CBUS Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Mar 20, 2025$2.19$2.05-6.39%
Nov 07, 2024$4.40$5.28+20.00%
Aug 08, 2024$7.46$7.02-5.90%
May 09, 2024$17.85$17.74-0.62%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Cibus (CBUS) report earnings?
Cibus (CBUS) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
    What is Cibus (CBUS) earnings time?
    Cibus (CBUS) earnings time is at May 08, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is CBUS EPS forecast?
          CBUS EPS forecast for the fiscal quarter 2025 (Q1) is -0.51.
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis